Abstract 12183: SLCO1B1 Genotype-Guided Statin Therapy Lowers LDL Cholesterol in Patients With Statin-Intolerance- A Randomized Controlled Trial
Publication Title
Circulation
Document Type
Presentation
Publication Date
2018
Keywords
washington; spokane
Abstract
Introduction: Statin-intolerance is a barrier to reducing cardiovascular disease risk. A genetic variant (*5, rs4149056) in the SLCO1B1 statin hepatic transporter gene is well characterized and linked to higher statin concentrations, statin-intolerance, and statin non-adherence. SLCO1B1*5 has a high negative predictive value for severe simvastatin myopathy; Pravastatin[P]/ fluvastatin[F]/ rosuvastatin[R] are preferred statins in *5 carriers to minimize side effects. The effects of SLCO1B1 genotype-guided statin therapy or delivery of SLCO1B1 genetic risk information are unknown.
Hypothesis: Genotype-guided statin therapy (GGST) is superior to usual care in patients with statin-intolerance for statin-related outcomes.
Methods: We randomly assigned 159 primary care patients with statin intolerance not prescribed statins to either GGST vs. usual care. GGST patients and their providers received *5 genetic risk information about statin side effects and genotype-specific statin prescription recommendations. Patients in the usual care arm received general information regarding statin risk and prescriptions. The outcomes measured at 3 and 8 months were statin re-initiation, LDL cholesterol (LDLc), and statin adherence using the validated Morisky Medication Adherence Survey.
Results: The median age was 64.0 years, 57% were female, 41% reported intolerance to > 1 statin, 75% reported myalgia with statins, and 25% were *5 carriers. Follow up was complete for 144 patients (91%) at 3-months and 118 (74%) at 8-months. At 3-months, GGST was associated with a higher proportion of patients who restarted statin therapy (55.4% vs. 38.0%, p=0.037), and lower LDLc (131.9±42.0 vs. 144.4±43.0, p=0.041), but similar statin adherence scores (p=0.96). Effects at 8-months were consistent with 3-month results for statin prescriptions (54% vs. 37%, p=0.07) and LDLc (128.6±37.9 vs. 141.0±44.4, p=0.07). Use of P/F/R was higher in *5 carriers assigned to GGST versus usual care (92% vs. 67%, p=0.24).
Conclusion: In primary care patients with statin-intolerance, SLCO1B1 genotype guided statin therapy is effective in lowering LDLc compared to usual care. GGST, however, did not improve statin adherence in those who re-initiated statin therapy.
Footnotes
Author Disclosures: D. Voora: Research Grant; Significant; NIH, AstraZeneca. E. Perry: None. K. Singh: None. G. Trujillo: None. N. Milazzo: None. D. Savard: None. S. Haga: None. M.D. Musty: None. Y. Li: None. B. Peyser: None.
Area of Special Interest
Cardiovascular (Heart)
Specialty/Research Institute
Cardiology
